Follow us on
Search News Archives
Monthly Newsletter

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Videos

 

Research & Case Studies

 

Literature

 

Events | Webinars

 

 

 

Conferences | Events

Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever

publication date: Jan 10, 2019
 | 
author/source: Batavia Biosciences

Batavia BiosciencesBatavia Biosciences announces that the International AIDS Vaccine Initiative (IAVI) and Batavia Biosciences will work together under a grant to advance the development of a Lassa fever vaccine.

With this grant, Batavia Biosciences will leverage its novel, highly intensified manufacturing technology to develop a low-cost, easy-to-implement manufacturing process. This process can facilitate rapid clinical development and establishment of a stockpile of an innovative new Lassa fever vaccine, which is based on the Vesicular Stomatitis Virus (VSV) vector system.

This partnership is Batavia Biosciences’ latest contribution to global health initiatives with its extensive biopharmaceutical development know-how and technologies to bring safe, new and improved medicines to the market as quickly as possible.

Lassa fever, also known as Lassa hemorrhagic fever, is endemic in West Africa and can spread from person to person via contact with bodily fluids. The Lassa virus is transmitted to humans mainly through handling rats, food or household items contaminated by rats’ urine. It causes a range of symptoms including vomiting, fever and bleeding. An estimated 100,000 to 300,000 Lassa fever cases are diagnosed annually, resulting in approximately 5,000 deaths. Despite this high morbidity and mortality, no vaccine for Lassa fever is currently available.

Lassa fever devastates lives and has far-reaching economic consequences. Vaccines are a vital part of the fight against them but their development is costly, complex and challenging.

Batavia Biosciences’ COO Dr Chris Yallop states: “It is an honor that IAVI has appointed Batavia Biosciences to partner in the development of such an innovative and potentially transformative vaccine production model.”

Batavia Biosciences’ CEO Dr Menzo Havenga concludes: “This partnership with IAVI is a further validation of our viral vector technology, and provides us with an opportunity to further develop a new global health solution on top of our contributions to the polio vaccine, rotavirus vaccine and novel biomanufacturing platforms all aiming at making biopharmaceuticals available and affordable to all.”



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners